<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of primary myelofibrosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of primary myelofibrosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of primary myelofibrosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary myelofibrosis (PMF) is one of the chronic myeloproliferative disorders, which are collectively characterized by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. PMF was previously called chronic idiopathic myelofibrosis (CIMF) and agnogenic myeloid metaplasia (AMM).</p><p>Acute myelofibrosis, a term that has been applied to the clinical picture occasionally seen in patients with acute megakaryoblastic leukemia (FAB M7), is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification", section on 'Acute megakaryoblastic leukemia'</a>.)</p><p>The clinical manifestations and diagnosis of PMF will be reviewed here. The pathogenetic mechanisms, prognosis, and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis"</a> and  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF"</a> and  <a class="medical medical_review" href="/z/d/html/104860.html" rel="external">"Prognosis of primary myelofibrosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PMF is the least frequent among the chronic myeloproliferative diseases. One study reported an estimated incidence of 1.5 per 100,000 per year in Olmsted County, Minnesota [<a href="#rid1">1</a>]. This incidence figure is higher than those reported from western Australia and northern Israel.</p><p>PMF occurs mainly in middle aged and older adults. The median age at presentation is 67 years [<a href="#rid1">1</a>]. Approximately 5 and 17 percent of the patients are diagnosed before the age of 40 and 50 years, respectively [<a href="#rid2">2</a>]. The condition is rare in childhood [<a href="#rid3">3</a>]; a familial occurrence has been reported in several kindreds. Both the familial and the idiopathic forms in childhood may be associated with congenital anomalies and chromosome abnormalities [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The most common presenting complaint in PMF is that of severe fatigue, occurring in 50 to 70 percent of patients (<a class="graphic graphic_table graphicRef75473" href="/z/d/graphic/75473.html" rel="external">table 1</a>) [<a href="#rid1">1,2,6-9</a>]. Symptoms due to an enlarged spleen have been described in 25 to 50 percent of patients, while a smaller number note weight loss and 5 to 20 percent experience other signs of a hypermetabolic state such as low grade fever, bone pain, and night sweats [<a href="#rid2">2,8</a>]. Approximately 15 to 30 percent are asymptomatic, with the diagnosis being made during investigation of splenomegaly (occurring in at least 90 percent of patients), hepatomegaly (40 to 70 percent), or abnormal blood findings [<a href="#rid2">2,8,9</a>]. Enlargement of the spleen and liver are due to the marked extramedullary hematopoiesis associated with PMF.</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension – Pulmonary hypertension has been detected in patients with PMF; while often asymptomatic, it has been associated with reduced overall survival [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus – In our series of 566 consecutive patients with PMF, pruritus was documented in 16 percent [<a href="#rid13">13</a>]. This symptom did not correlate with karyotype, risk category, overall survival, leukemic transformation, or plasma levels of 20 cytokines known to be abnormally expressed in PMF.</p><p></p><p>A symptom assessment form has been devised for measuring clinical improvement in therapeutic trials [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H19956477"><span class="h3">Thrombotic events</span><span class="headingEndMark"> — </span>The incidence of arterial and venous thrombotic events in PMF (2 per 100 patient-years) is approximately the same as that seen in essential thrombocythemia (1 to 3 per 100 patient-years), and significantly lower than that seen in polycythemia vera (5.5 per 100 patient-years) [<a href="#rid15">15</a>]. In a retrospective analysis of 205 patients with PMF, 13.2 percent had experienced a thrombotic event at or prior to their diagnosis, and 10.7 percent developed post-diagnosis thrombosis at a median follow-up of 31 months [<a href="#rid16">16</a>]. On multivariate analysis, a history of thrombosis was the only predictive variable; 71 percent of the venous events were temporally associated with other exogenous risk factors for thrombosis (eg, surgery, central line placement, hormonal therapy).</p><p class="headingAnchor" id="H5"><span class="h2">Splenomegaly</span><span class="headingEndMark"> — </span>Splenomegaly, often marked, is the hallmark of PMF [<a href="#rid17">17</a>]. The spleen may be so large that its lower border is below the pelvic brim and its right border extends across the midline. In two series, 38 percent of patients had splenomegaly that extended more than 10 cm below the left costal margin [<a href="#rid18">18</a>], and 23 percent had massive splenomegaly that extended over 16 cm below the left costal margin [<a href="#rid2">2</a>].</p><p>Symptoms due to splenic disease often figure prominently in PMF. Patients may note a dragging or heavy sensation in the left upper abdomen, and the spleen may compress the patient's stomach, leading to early satiety. Severe left upper quadrant pain, with or without left shoulder pain, may result from multiple and/or recurrent episodes of splenic infarction or inflammation of the tissues surrounding the spleen (ie, perisplenitis).</p><p class="headingAnchor" id="H6"><span class="h2">Hepatomegaly</span><span class="headingEndMark"> — </span>Palpable hepatomegaly is present in 40 to 70 percent of patients. Portal hypertension may develop as a result of increased splanchnic flow due to splenomegaly and/or intrahepatic obstruction associated with extramedullary hematopoiesis [<a href="#rid19">19</a>]. Complications include ascites, esophageal and gastric varices, gastrointestinal bleeding, and hepatic encephalopathy.</p><p>Portal vein thrombosis is a recognized complication of PMF and other chronic myeloproliferative disorders [<a href="#rid19">19</a>] and may precede the clinical onset of the disease, similar to what has been documented in polycythemia vera [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Extramedullary hematopoiesis</span><span class="headingEndMark"> — </span>Foci of extramedullary hematopoiesis may occur in almost any organ [<a href="#rid21">21-23</a>]. Organ involvement may present as splenomegaly, hepatomegaly, lymphadenopathy; pleural, pericardial, or abdominal effusions; or involvement of the gastrointestinal or genitourinary tracts or lung, leading to symptoms such as dysuria and respiratory distress [<a href="#rid24">24-28</a>]. Involvement of the central nervous system may be associated with increased intracranial pressure, altered sensorium, motor and sensory impairment, including cord compression [<a href="#rid29">29,30</a>].</p><p>Involvement of the skin is rare but may present as erythematous plaques, nodules, erythema, ulcers, or bullae [<a href="#rid31">31,32</a>]. In a literature review of 13 such cases, nine showed that all three hematopoietic cell lines (myeloid, erythroid, and megakaryocytic) were present in these lesions [<a href="#rid33">33</a>].</p><p>In our series of 27 patients with an antemortem diagnosis of extramedullary hematopoiesis other than in the liver or spleen, involved sites were as follows [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In or surrounding the vertebral column (especially thoracic) – 7</p><p class="bulletIndent1"><span class="glyph">●</span>Lymph nodes – 4</p><p class="bulletIndent1"><span class="glyph">●</span>Retroperitoneum – 4</p><p class="bulletIndent1"><span class="glyph">●</span>Lungs or pleura – 3</p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary system – 2</p><p class="bulletIndent1"><span class="glyph">●</span>Skin – 2</p><p class="bulletIndent1"><span class="glyph">●</span>Other sites (thalamus, right atrium, mouth, muscle, bowel) – 5</p><p></p><p>Foci of extramedullary hematopoiesis may develop and/or enlarge significantly after splenectomy, perhaps due to the loss of filtering function of the spleen [<a href="#rid34">34,35</a>]. This may be especially critical in the liver [<a href="#rid26">26,36</a>]. As an example, a study of 10 patients with PMF undergoing splenectomy found hepatic extramedullary hematopoiesis in all those in whom an intraoperative liver biopsy was performed [<a href="#rid36">36</a>]. Following splenectomy, a significant increase in liver size and in serum concentrations of alkaline phosphatase, bilirubin, and/or gamma-glutamyl transpeptidase were seen in all patients. Two patients developed acute liver failure and died three and four weeks postsplenectomy. In contrast, no liver changes were observed in 10 patients with chronic myeloid leukemia who also underwent splenectomy. </p><p class="headingAnchor" id="H8"><span class="h2">Bone and joint involvement</span><span class="headingEndMark"> — </span>A number of skeletal changes may accompany the marrow fibrosis in PMF. These abnormalities may be asymptomatic but can cause severe bone and joint tenderness or pain, especially in the lower extremities, that is difficult to treat.</p><p class="bulletIndent1"><span class="glyph">●</span>Osteosclerosis is characterized by a diffuse or patchy increase in bone density on radiologic studies and increased prominence of bony trabeculae. A mottled radiographic appearance of the bone has been described in 25 to 66 percent of patients with PMF [<a href="#rid8">8</a>]. This pattern may be confused with metastatic carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periostitis can lead to debilitating bony pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cortical bone blood flow is considerably increased in PMF, resulting in a "superscan" phenomenon on bone scintigraphy. It is often clinically evident as an increase in warmth over the tibiae and knees.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary gout due to chronic overproduction of uric acid can lead to acute monoarticular or chronic polyarticular arthritis. (See  <a class="medical medical_review" href="/z/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteolytic lesions are rare, and usually reflect the presence of a solitary myeloid sarcoma, also called granulocytic sarcoma or chloroma [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Myeloid sarcoma'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">LABORATORY FINDINGS</span></p><p class="headingAnchor" id="H10"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Anemia with hemoglobin less than 10 g/dL is seen in approximately 50 percent of patients with PMF, and 20 percent present with a hemoglobin less than 8 g/dL [<a href="#rid2">2</a>]. The causes are multiple and include:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in medullary erythropoietic sites</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ineffective erythropoiesis associated with extramedullary sites of red blood cell (RBC) production</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Splenic sequestration and destruction of circulating RBCs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding due to thrombocytopenia or other complications such as varices resulting from portal vein thrombosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hemolysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilutional "anemia" may be present in patients with large spleens and expanded plasma volumes, but normal RBC mass</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influence of thrombopoietin receptor (Mpl) mutations [<a href="#rid38">38</a>]</p><p></p><p>One or more of the above mechanisms may be responsible for anemia in any particular patient. A number of isotopic techniques are available for assessment of these mechanisms but are rarely used [<a href="#rid39">39</a>].</p><p>After the onset of anemia, most patients experience a progressive decline in the hemoglobin concentration, requiring frequent RBC transfusions. The peripheral smear is quite characteristic, showing anisocytosis (ie, RBCs of varying size), poikilocytosis (ie, RBCs of varying shape), teardrop-shaped RBCs (dacrocytes), nucleated RBCs, and variable degrees of polychromasia (<a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef55274" href="/z/d/graphic/55274.html" rel="external">picture 2</a>). Why dacrocytes form in PMF is not understood; splenectomy and chemotherapy reduce, but do not eliminate, the number of such cells in the circulation [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Platelet and white blood cell abnormalities</span><span class="headingEndMark"> — </span>The platelet and white blood cell (WBC) counts are variable in PMF. Marked leukocytosis (WBC &gt;30,000/microL) and thrombocytosis (platelet count &gt;500,000/microL) occur at diagnosis in approximately 11 and 13 percent of patients, respectively, while leukopenia and thrombocytopenia are seen in 8 and 26 percent, respectively [<a href="#rid2">2,18</a>]. The variable leukocyte count reflects variation in the number of neutrophils. Immature cells from the neutrophilic series are always present as part of the leukoerythroblastic blood picture and myeloblasts may be seen in the peripheral smear, usually amounting to less than 5 percent of the total WBC count (<a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">picture 1</a>). Hypersegmented neutrophils may also be seen (<a class="graphic graphic_picture graphicRef58820" href="/z/d/graphic/58820.html" rel="external">picture 3</a>).</p><p>Thrombocytopenia becomes more common with disease progression. Platelets may be abnormally large with altered granulation; in addition, fragmented megakaryocytes are also seen on the peripheral smear. Abnormal platelet function is common [<a href="#rid42">42</a>] although the correlation between these abnormalities and clinical bleeding is weak.</p><p>Bleeding complications are usually associated with thrombocytopenia, esophageal or gastric varices, the use of nonsteroidal anti-inflammatory drug, and/or acquired deficiency of factor V [<a href="#rid43">43</a>]. A few patients have mild prolongation of the prothrombin and partial thromboplastin times along with decreased levels of factor V and VIII. Laboratory features of disseminated intravascular coagulation (DIC) may accompany these abnormalities and may not be apparent until surgery is performed. Extreme thrombocytosis (ie, platelets &gt;1 million/microL) may promote a hemostatic defect due to the excessive adsorption of large von Willebrand factor multimers, such as that seen in essential thrombocythemia. (See  <a class="medical medical_review" href="/z/d/html/4486.html" rel="external">"Essential thrombocythemia: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Circulating CD34+ cells</span><span class="headingEndMark"> — </span>In an Italian multicenter study, the median absolute number of circulating CD34+ hematopoietic precursor cells in 84 consecutive patients with PMF (92 CD34+ cells/microL; range: 0 to 2460) was 400 times that of healthy normal subjects (normal range: 0.15 to 0.35 cells/microL) [<a href="#rid44">44</a>]. A value of 15 CD34+ cells/microL in patients not on therapy could be used diagnostically to separate patients with PMF from those with Philadelphia chromosome negative chronic myeloproliferative diseases, with positive and negative predictive values of 98 and 85 percent, respectively.</p><p>In this study, CD34+ counts progressively increased as disease severity increased; overall survival and the interval to blast crisis were significantly shorter in patients with &gt;300 CD34+ cells/microL. However, our serial studies in 94 patients did not support an independent prognostic value for peripheral blood CD34 counts in PMF [<a href="#rid45">45</a>].</p><p>Circulating endothelial progenitor cells with CD34, CD133, and VEGF receptor-2 positivity have also been detected in patients with PMF [<a href="#rid46">46</a>]. Their significance is unclear.</p><p class="headingAnchor" id="H13"><span class="h2">Abnormal laboratory tests</span><span class="headingEndMark"> — </span>Patients with PMF may have nonspecific abnormalities in a variety of laboratory tests. These include: elevations in the serum concentrations of alkaline phosphatase, lactate dehydrogenase, uric acid, leukocyte alkaline phosphatase, and vitamin B12 [<a href="#rid47">47,48</a>]. The increase in alkaline phosphatase may be due to liver involvement or bone disease, the increase in lactate dehydrogenase may result from ineffective hematopoiesis, hyperuricemia is due to enhanced turnover of hematopoietic tissue and can cause gout or uric acid stones, and the increase in serum vitamin B12 reflects an increased neutrophil mass.</p><p class="headingAnchor" id="H14"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>There are a number of methodologies available for evaluation of marrow involvement in patients with PMF; although, as will be described in the next section, the diagnosis is often strongly suspected from the clinical presentation alone. Furthermore, the bone marrow may not reveal extensive replacement of the marrow by fibrosis, which has classically been considered to be the hallmark of the disease.</p><p>Marrow can be aspirated and/or biopsied directly, and it can be imaged with magnetic resonance imaging (MRI) or scintigraphy. These techniques can be used for initial diagnosis and prognosis, and for monitoring the course of the disease.</p><p class="headingAnchor" id="H15"><span class="h3">Bone marrow aspiration</span><span class="headingEndMark"> — </span>The bone marrow in PMF is often difficult to aspirate, usually yielding a "dry" tap. In addition, the results of aspiration alone, if successful, are not diagnostic. The most common findings are neutrophilic and megakaryocytic hyperplasia.</p><p>Megakaryocytes are often morphologically abnormal with both micro- and macro-megakaryocytes. Granulocytes may show hyperlobulation, and erythroid precursors may be normal or increased. These morphologic changes in megakaryocytes help to distinguish early/prefibrotic PMF from essential thrombocythemia. (See <a class="local">'Other chronic myeloid disorders'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h3">Bone marrow biopsy</span><span class="headingEndMark"> — </span>Bone marrow biopsy is necessary to demonstrate fibrosis (<a class="graphic graphic_picture graphicRef57384" href="/z/d/graphic/57384.html" rel="external">picture 4</a>) [<a href="#rid49">49-51</a>]. Some degree of fibrosis is seen in almost all patients; the fibrosis is typically extensive and visualized better with a silver stain (reticulin) or a trichrome stain (mature collagen) (<a class="graphic graphic_picture graphicRef69139" href="/z/d/graphic/69139.html" rel="external">picture 5</a>). Bone marrow sinusoids are expanded and there is intravascular hematopoiesis. The fibrosis is generally associated with atypical megakaryocytic hyperplasia and thickening and distortion of the bony trabeculae (osteosclerosis).</p><p>Semiquantitative grading of bone marrow fibrosis (<a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>) is critical for distinguishing between overt PMF and pre-PMF (<a class="graphic graphic_table graphicRef110227" href="/z/d/graphic/110227.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 4</a>).</p><p>In some patients, however, the bone marrow is markedly hypercellular with scant bone marrow fibrosis; this is called the cellular phase of PMF. The diagnosis of PMF in this setting is made from the clinical and peripheral smear findings after chronic myeloid leukemia and polycythemia vera have been excluded.</p><p class="headingAnchor" id="H17"><span class="h3">Bone marrow imaging with MRI</span><span class="headingEndMark"> — </span>The major source of the MRI signal from bone is the fat and water content of bone marrow, with little or no signal arising from bone or normal marrow cells. Thus, MRI can demonstrate conversion of fatty marrow (intense or bright signal) to cellular and/or fibrotic marrow (markedly low intensity signal) [<a href="#rid52">52,53</a>]. However, the value of this technique for replacing bone marrow biopsy or for staging or prognostic purposes is not clear [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Isotopic marrow imaging</span><span class="headingEndMark"> — </span>Erythropoietically active marrow can be directly imaged using isotopes of iron (Fe-52 or Fe-59) or indium (In-111) [<a href="#rid55">55</a>]. These techniques may be useful for determining patterns of marrow loss, extension into the long bones, or sites of extramedullary erythropoiesis.</p><p class="headingAnchor" id="H19"><span class="h2">Gene mutations</span><span class="headingEndMark"> — </span>As with other myeloproliferative neoplasms, the vast majority of patients with PMF demonstrate mutually exclusive mutations in <em>JAK2</em>, <em>MPL</em>, or <em>CALR</em>. Rough estimates for the frequency at which these genes are mutated in PMF are as follows [<a href="#rid56">56-59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2</em> mutation – 60 to 65 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>CALR</em> mutation – 20 to 25 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>MPL</em> mutation – 5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation ("triple negative") – 8 to 10 percent</p><p></p><p>A minority of "triple negative" PMF has non-canonical mutations in <em>JAK2</em>, <em>MPL</em>, and other genes on whole exome sequencing [<a href="#rid60">60</a>]. Further study is needed to elucidate the function of these other gene mutations in the pathogenesis of disease. The role of gene mutations on the pathogenesis of myeloproliferative neoplasms is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'Mutations in PV, ET, and PMF'</a>.)</p><p>Presence of these mutations, their allele burden, and their relationship to clinical manifestations, overall survival, and leukemic transformation, are under active investigation. </p><p class="headingAnchor" id="H20"><span class="h1">TRANSFORMATION TO ACUTE LEUKEMIA</span><span class="headingEndMark"> — </span>Acute leukemia occurs as a terminal event in a minority of patients with PMF, but it is the most commonly identified cause of death [<a href="#rid61">61,62</a>]. Many of these patients have not had prior treatment with alkylating agents or radiotherapy [<a href="#rid63">63-67</a>]. Most of the leukemic transformations have been of myeloid origin; however, lymphoid, erythroid, megakaryocytic, and mixed lineage leukemias have occasionally been described. Localized foci of leukemic blasts (ie, myeloid sarcoma, also called granulocytic sarcoma or chloroma) are rarely seen in PMF.</p><p>The largest reported experience comes from our series of 2333 consecutive patients with PMF, 91 of whom (3.9 percent) fulfilled criteria for acute leukemic transformation; all were myeloid in origin [<a href="#rid63">63</a>]. A clonal abnormality was present in 49 of the 51 patients in whom cytogenetic studies were performed, and karyotypic evolution was documented in the majority of patients with serial studies.</p><p>In a separate analysis of 311 patients with PMF, the following two factors at the time of diagnosis were independent predictors of leukemic transformation [<a href="#rid68">68</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Circulating blasts ≥3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;100,000/microL</p><p></p><p>In this series, 77, 19, and 4 percent of patients had none, one, or both of these risk factors, respectively, with rates of leukemic transformation of 6, 18, and 18 percent, respectively. Treatment-related factors included use of an erythropoiesis-stimulating agent and <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>.</p><p>Establishing the presence of leukemic transformation in PMF is often difficult, primarily because abnormal cell counts and immature cells in the peripheral blood are part of the disease process. Furthermore, bone marrow biopsy may not reveal clear evidence of leukemia. In such patients, the diagnosis is established from tissue leukemic deposits or at autopsy.</p><p>Management of leukemic transformation of PMF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF", section on 'Leukemic transformation'</a>.)</p><p class="headingAnchor" id="H3141935"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H1769962742"><span class="h2">Suspecting PMF</span><span class="headingEndMark"> — </span>Patients with PMF first come to medical attention with some constellation of the following findings: nonspecific systemic symptoms, splenomegaly, hepatomegaly (both due to extramedullary hematopoiesis), anemia, and either high or low platelet and white blood cell (WBC) counts (<a class="graphic graphic_table graphicRef75473" href="/z/d/graphic/75473.html" rel="external">table 1</a>). The peripheral smear provides the first clue to the diagnosis of PMF. The characteristic features include teardrop-shaped red blood cells and the characteristic leukoerythroblastic findings of myelophthisis (replacement of normal marrow elements by fibrosis or tumor), nucleated erythrocytes and granulocyte precursors (myelocytes, metamyelocytes, and blasts) (<a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">picture 1</a>).</p><p>However, a similar blood picture can be produced by bone marrow infiltration by metastatic cancer (especially prostate or breast) or infectious granulomata. Thus, bone marrow biopsy is required for demonstration of fibrosis and the absence of clusters of malignant cells (<a class="graphic graphic_picture graphicRef70576" href="/z/d/graphic/70576.html" rel="external">picture 6</a>) or granulomata.</p><p>There is no "gold standard" for the diagnosis of PMF, although criteria have been proposed by the Italian Society of Hematology, the World Health Organization (WHO), and others [<a href="#rid50">50,69-72</a>].</p><p>The 2016 revisions to the WHO criteria offer diagnostic criteria for pre-PMF and overt PMF (<a class="graphic graphic_table graphicRef110227" href="/z/d/graphic/110227.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 4</a>) [<a href="#rid50">50,72-74</a>]. These are described in the following sections. The distinction between these entities is important because they differ in regard to patterns of presentation, survival, and disease progression [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2459448225"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The diagnosis of both overt PMF and pre-PMF requires bone marrow biopsy (including semiquantitative evaluation of fibrosis) and molecular analysis. It is our practice to include the following in the initial evaluation of a patient with suspected PMF:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – Focused history including an assessment of constitutional symptoms, disease tempo (with prior blood counts when available), prior transfusions, thrombotic/hemorrhagic events, and cardiovascular risk factors. Physical examination should include an assessment of spleen size by palpation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – Laboratory studies include a complete blood count with differential and review of the peripheral smear, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), and uric acid. Peripheral blood fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) for <em>BCR::ABL1</em> is sent to exclude chronic myeloid leukemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow examination</strong> – Unilateral bone marrow aspirate and biopsy. This sample should be sent for pathologic review with trichrome and reticulin stains, cytogenetics, and molecular testing for <em>JAK2</em> mutations. If <em>JAK2</em> testing is negative, molecular testing is performed for <em>CALR</em> and <em>MPL</em> mutations. If these are negative and the diagnosis is still suspected, identification of other gene mutations may offer proof of clonality (<em>ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2</em>, or <em>SR3B1</em> mutation).</p><p></p><p class="headingAnchor" id="H464939384"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria distinguish overt PMF from early/prefibrotic PMF [<a href="#rid76">76,77</a>]. </p><p class="headingAnchor" id="H2844422890"><span class="h3">Overt PMF</span><span class="headingEndMark"> — </span>Diagnosis of overt PMF requires all three of the following major criteria and at least one minor criterion (<a class="graphic graphic_table graphicRef110227" href="/z/d/graphic/110227.html" rel="external">table 3</a>) [<a href="#rid76">76,77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major criteria:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3 (<a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>WHO criteria for polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), or other myeloid neoplasm not met.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of a <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation <strong>or</strong> another clonal marker (<em>ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2</em>, or <em>SR3B1</em> mutation) <strong>or</strong> no identifiable cause of reactive fibrosis (eg, infection, autoimmune disorder, chronic inflammatory disorder, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or chronic toxic myelopathy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria</strong> (confirmed in two consecutive measurements):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia not attributable to a comorbid condition</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leukocytosis ≥11 x 10<sup>9</sup>/L (&gt;11,000/microL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palpable splenomegaly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LDH above the upper limit of normal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leukoerythroblastosis</p><p></p><p class="headingAnchor" id="H2773802486"><span class="h3">Pre-PMF</span><span class="headingEndMark"> — </span>Diagnosis of early/prefibrotic PMF requires all three of the following major criteria and at least one minor criterion (<a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 4</a>) [<a href="#rid76">76,77</a>]. The diagnosis can be challenging as the presentation can mimic that of ET. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major criteria:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Megakaryocytic proliferation and atypia, without reticulin fibrosis &gt;grade 1, accompanied by increased age-adjusted bone marrow cellularity, granulocyte proliferation, and often decreased erythropoiesis. Grade 1 myelofibrosis is a loose network of reticulin with many intersections, especially in perivascular areas (<a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Criteria for PV, ET, CML, MDS, or other myeloid neoplasm not met.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of a <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation <strong>or</strong> another clonal marker (<em>ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2</em>, or <em>SR3B1</em> mutation) <strong>or</strong> no identifiable cause of reactive fibrosis (eg, infection, autoimmune disorder, chronic inflammatory disorder, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or chronic toxic myelopathy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria</strong> (must be confirmed in two consecutive measurements):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia not attributable to a comorbid condition</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leukocytosis ≥11 x 10<sup>9</sup>/L (&gt;11,000/microL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palpable splenomegaly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LDH above the upper limit of normal</p><p></p><p>Distinction of pre-PMF from overt PMF is important because patients who present with pre-PMF have different patterns of clinical presentation, survival, and disease progression [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H21"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There are several other causes of bone marrow fibrosis that should be considered before the diagnosis of PMF is confirmed. PMF must be distinguished from rare cases of acute myelofibrosis and from other causes of chronic myelofibrosis.</p><p class="headingAnchor" id="H3692930157"><span class="h2">Acute myelofibrosis</span><span class="headingEndMark"> — </span>Acute myelofibrosis is a very rare form of acute myeloid leukemia (AML). It is characterized by the rapid onset of severe bone marrow fibrosis associated with fever and pancytopenia, teardrop-shaped red blood cells, and a leukoerythroblastic blood picture [<a href="#rid78">78,79</a>]. However, unlike PMF, the spleen is often not palpable in acute myelofibrosis and in some instances the bone marrow may show excess megakaryoblasts, suggesting a diagnosis of acute megakaryoblastic leukemia (FAB classification M7). This distinction is critical since the appropriate treatment for acute myelofibrosis is induction chemotherapy with or without hematopoietic cell transplantation. (See  <a class="medical medical_review" href="/z/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p class="headingAnchor" id="H4249748774"><span class="h2">Other chronic myeloid disorders</span><span class="headingEndMark"> — </span>PMF must be distinguished from other chronic myeloid disorders that may also be accompanied by substantial bone marrow fibrosis. These include polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and mast cell disease [<a href="#rid47">47,80-84</a>]. It is therefore imperative that careful morphologic and cytogenetic examination be carried out before a diagnosis of PMF is made [<a href="#rid50">50,51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of the Philadelphia (Ph) chromosome by conventional cytogenetics or the <em>BCR::ABL1</em> fusion signal by molecular genetics testing (FISH, PCR, sequencing) mandates a diagnosis of CML. (See  <a class="medical medical_review" href="/z/d/html/4537.html" rel="external">"Molecular genetics of chronic myeloid leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of dyserythropoiesis (dysplastic bone marrow hyperplasia or even occasional hypoplasia, associated with variable degrees of peripheral blood cytopenia with or without monocytosis) suggests a diagnosis of MDS, especially in the absence of splenomegaly [<a href="#rid81">81,82</a>]. Chronic myelomonocytic leukemia (CMML) has features of both MDS and MPN, with dysplastic changes, monocytosis, hepatosplenomegaly, and lymphadenopathy. (See  <a class="medical medical_review" href="/z/d/html/96031.html" rel="external">"Chronic myelomonocytic leukemia: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The traditional group of Ph-negative chronic myeloproliferative neoplasms includes PMF, PV, and ET. Among these three disorders, PV is readily identified by the presence of an increased red cell mass. The differentiation between PMF and ET is dependent primarily on bone marrow morphology, the degree of bone marrow fibrosis and splenomegaly, and the presence of peripheral blood leukoerythroblastosis in PMF [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early/prefibrotic PMF can mimic ET in its presentation; careful morphologic examination is necessary for distinguishing between the two (<a class="graphic graphic_table graphicRef110225" href="/z/d/graphic/110225.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 4</a>). Megakaryocytes are large and mature-appearing in ET, while those in prefibrotic PMF display abnormal maturation with hyperchromatic and irregularly folded nuclei [<a href="#rid86">86,87</a>]. This distinction is important since, in two studies, thrombotic complications, overall survival, leukemic transformation, and rates of progression to overt myelofibrosis were significantly worse in prefibrotic PMF [<a href="#rid88">88,89</a>]. (See <a class="local">'Pre-PMF'</a> above.)</p><p></p><p class="headingAnchor" id="H2861686207"><span class="h2">Secondary myelofibrosis (post-PV or post-ET)</span><span class="headingEndMark"> — </span>Patients with PV and ET can develop bone marrow fibrosis mimicking that of PMF. An International Working Group for Myelofibrosis Research and Treatment proposed the following criteria for the diagnosis of post-PV and post-ET myelofibrosis [<a href="#rid90">90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major criteria</strong> (both required):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documentation of a previous diagnosis of either PV or ET as defined by WHO criteria</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of increased bone marrow fibrosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria</strong> (at least two required):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive anemia or loss of phlebotomy requirement</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leukoerythroblastic blood picture</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increasing degree of splenomegaly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Development of constitutional symptoms (ie, weight loss, night sweats, unexplained fever)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased serum LDH (post-ET myelofibrosis only)</p><p></p><p class="headingAnchor" id="H13251875"><span class="h2">Other hematologic conditions</span><span class="headingEndMark"> — </span>Other hematologic conditions associated with bone marrow fibrosis include hairy cell leukemia, lymphoma, and multiple myeloma [<a href="#rid91">91-94</a>].</p><p>A small percentage of patients with immune thrombocytopenia (ITP) will develop marrow fibrosis after treatment with the thrombopoiesis-stimulating agents <a class="drug drug_general" data-topicid="9493" href="/z/d/drug information/9493.html" rel="external">romiplostim</a> and <a class="drug drug_general" data-topicid="9051" href="/z/d/drug information/9051.html" rel="external">eltrombopag</a> [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/6678.html" rel="external">"Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults", section on 'TPO receptor agonists'</a>.)</p><p class="headingAnchor" id="H13251881"><span class="h2">Non-hematologic conditions</span><span class="headingEndMark"> — </span>Non-hematologic causes of bone marrow fibrosis are rare and include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy metastatic to the bone marrow [<a href="#rid96">96-98</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune disorders (eg, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polymyositis) and primary pulmonary hypertension [<a href="#rid99">99-106</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary hyperparathyroidism associated with vitamin D deficiency [<a href="#rid107">107,108</a>] or renal osteodystrophy [<a href="#rid109">109-111</a>]</p><p></p><p class="headingAnchor" id="H2106002335"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116776.html" rel="external">"Society guideline links: Myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by a leukoerythroblastic blood smear, proliferation of abnormal bone marrow megakaryocytes and granulocytes, variable marrow fibrosis, and extramedullary hematopoiesis with marked splenomegaly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – PMF usually presents in middle-aged and older adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Severe fatigue is most common, but some patients have symptoms from an enlarged spleen, weight loss, constitutional symptoms, pulmonary hypertension, pruritus, or thrombosis; a minority of patients are asymptomatic. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – Anemia is present in half of patients. White blood cell (WBC) and platelet counts are variable; some patients have marked leukocytosis and/or thrombocytosis, while others have leukopenia and/or thrombocytopenia. Immature neutrophils are present as part of the leukoerythroblastic blood picture and myeloblasts may be seen on the blood smear. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Bone marrow is often difficult to aspirate, yielding a "dry" tap. </p><p></p><p class="bulletIndent1">Bone marrow biopsy demonstrates fibrosis (<a class="graphic graphic_picture graphicRef57384" href="/z/d/graphic/57384.html" rel="external">picture 4</a>), which is best visualized with silver stain (reticulin) or trichrome stain (mature collagen) (<a class="graphic graphic_picture graphicRef69139" href="/z/d/graphic/69139.html" rel="external">picture 5</a>). (See <a class="local">'Bone marrow biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular abnormalities</strong> – <em>JAK2</em> mutation is present in two-thirds of patients, <em>CALR</em> mutation in one-quarter, <em>MPL</em> mutation in 5 percent, and "triple negative" disease (ie, no <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation) in 10 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect PMF</strong> – PMF should be suspected in a patient with splenomegaly with circulating granulocyte precursors (myelocytes, metamyelocytes, and blasts), nucleated red blood cells (RBCs), and teardrop-shaped RBCs in peripheral blood. (See <a class="local">'Suspecting PMF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – PMF diagnosis requires all of the following (<a class="graphic graphic_table graphicRef110227" href="/z/d/graphic/110227.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef110226" href="/z/d/graphic/110226.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>) (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow</strong> – Megakaryocyte proliferation and atypia, usually accompanied by reticulin and/or collagen fibrosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exclude other MPNs</strong> – Criteria for polycythemia vera (PV), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), or other myeloid neoplasm are not met.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clonality</strong> – Demonstration of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation or another clonal marker.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Minor criteria</strong> – At least one of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>WBC ≥11 x 10<sup>9</sup>/L</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Palpable splenomegaly</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anemia not attributable to another condition</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased serum lactate dehydrogenase (LDH)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Leukoerythroblastosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Criteria to distinguish prefibrotic PMF from overt PMF, based on the degree of fibrosis (<a class="graphic graphic_table graphicRef110228" href="/z/d/graphic/110228.html" rel="external">table 2</a>) and leukoerythroblastosis are described. (See <a class="local">'Overt PMF'</a> above and <a class="local">'Pre-PMF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – PMF must be distinguished from rare cases of acute myelofibrosis, other causes of chronic myelofibrosis, and other MPNs. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H229038842"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61:10.</a></li><li><a class="nounderline abstract_t">Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75:4.</a></li><li><a class="nounderline abstract_t">DeLario MR, Sheehan AM, Ataya R, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults. Am J Hematol 2012; 87:461.</a></li><li><a class="nounderline abstract_t">Mallouh AA, Sa'di AR. Agnogenic myeloid metaplasia in children. Am J Dis Child 1992; 146:965.</a></li><li><a class="nounderline abstract_t">Bonduel M, Sciuccati G, Torres AF, et al. Familial idiopathic myelofibrosis and multiple hemangiomas. Am J Hematol 1998; 59:175.</a></li><li><a class="nounderline abstract_t">Smith RE, Chelmowski MK, Szabo EJ. Myelofibrosis: a review of clinical and pathologic features and treatment. Crit Rev Oncol Hematol 1990; 10:305.</a></li><li><a class="nounderline abstract_t">Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97:635.</a></li><li class="breakAll">Silverstein MN. Agnogenic myeloid metaplasia, Publishing Sciences Group, Acton, MA 1975.</li><li><a class="nounderline abstract_t">Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983; 62:353.</a></li><li><a class="nounderline abstract_t">García-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999; 60:130.</a></li><li><a class="nounderline abstract_t">Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120:801.</a></li><li><a class="nounderline abstract_t">Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008; 22:646.</a></li><li><a class="nounderline abstract_t">Vaa BE, Wolanskyj AP, Roeker L, et al. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol 2012; 87:136.</a></li><li><a class="nounderline abstract_t">Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011; 117:4869.</a></li><li><a class="nounderline abstract_t">Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115:778.</a></li><li><a class="nounderline abstract_t">Elliott MA, Pardanani A, Lasho TL, et al. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica 2010; 95:1788.</a></li><li><a class="nounderline abstract_t">O'Reilly RA. Splenomegaly in 2,505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2,056 patients. West J Med 1998; 169:78.</a></li><li><a class="nounderline abstract_t">Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013.</a></li><li><a class="nounderline abstract_t">Wanless IR, Peterson P, Das A, et al. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990; 12:1166.</a></li><li><a class="nounderline abstract_t">Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94:1063.</a></li><li class="breakAll">Lichtman MA. Idiopathic myelofibrosis (agnogenic myeloid metaplasia). In: Williams' Hematology, 5th ed, Beutler E, Lichtman MA, Coller BS, Kipps TJ (Eds), McGraw-Hill, New York 1995. p.331.</li><li><a class="nounderline abstract_t">Georgiades CS, Neyman EG, Francis IR, et al. Typical and atypical presentations of extramedullary hemopoiesis. AJR Am J Roentgenol 2002; 179:1239.</a></li><li><a class="nounderline abstract_t">Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003; 78:1223.</a></li><li><a class="nounderline abstract_t">Bartlett RP, Greipp PR, Tefferi A, et al. Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 1995; 70:1161.</a></li><li><a class="nounderline abstract_t">Knobel B, Melamud E, Virag I, Meytes D. Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature. Acta Haematol 1993; 89:104.</a></li><li><a class="nounderline abstract_t">Lioté F, Yeni P, Teillet-Thiebaud F, et al. Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature. Am J Med 1991; 90:111.</a></li><li><a class="nounderline abstract_t">Yusen RD, Kollef MH. Acute respiratory failure due to extramedullary hematopoiesis. Chest 1995; 108:1170.</a></li><li><a class="nounderline abstract_t">Richters ML. Myelofibrosis, diffuse alveolar hemorrhage and radiation treatment. Am J Hematol 2013; 88:922.</a></li><li><a class="nounderline abstract_t">Lundh B, Brandt L, Cronqvist S, Eyrich R. Intracranial myeloid metaplasia in myelofibrosis. Scand J Haematol 1982; 28:91.</a></li><li><a class="nounderline abstract_t">Koch BL, Bisset GS 3rd, Bisset RR, Zimmer MB. Intracranial extramedullary hematopoiesis: MR findings with pathologic correlation. AJR Am J Roentgenol 1994; 162:1419.</a></li><li><a class="nounderline abstract_t">Loewy G, Mathew A, Distenfeld A. Skin manifestation of agnogenic myeloid metaplasia. Am J Hematol 1994; 45:167.</a></li><li><a class="nounderline abstract_t">Pecci A, Croci G, Balduini CL, Boveri E. Cutaneous involvement by post-polycythemia vera myelofibrosis. Am J Hematol 2014; 89:448.</a></li><li><a class="nounderline abstract_t">Mizoguchi M, Kawa Y, Minami T, et al. Cutaneous extramedullary hematopoiesis in myelofibrosis. J Am Acad Dermatol 1990; 22:351.</a></li><li><a class="nounderline abstract_t">Fedeli G, Certo M, Cannizzaro O, et al. Extramedullary hematopoiesis involving the esophagus in myelofibrosis. Am J Gastroenterol 1990; 85:1512.</a></li><li><a class="nounderline abstract_t">Schreibman D, Brenner B, Jacobs R, et al. Small intestinal myeloid metaplasia. JAMA 1988; 259:2580.</a></li><li><a class="nounderline abstract_t">López-Guillermo A, Cervantes F, Bruguera M, et al. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991; 85:184.</a></li><li><a class="nounderline abstract_t">Hermann G, Feldman F, Abdelwahab IF, Klein MJ. Skeletal manifestations of granulocytic sarcoma (chloroma). Skeletal Radiol 1991; 20:509.</a></li><li><a class="nounderline abstract_t">Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137:244.</a></li><li><a class="nounderline abstract_t">Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol 1978; 40:205.</a></li><li><a class="nounderline abstract_t">DiBella NJ, Silverstein MN, Hoagland HC. Effect of splenectomy on teardrop-shaped erythrocytes in agnogenic myeloid metaplasia. Arch Intern Med 1977; 137:380.</a></li><li><a class="nounderline abstract_t">Manoharan A, Hargrave M, Gordon S. Effect of chemotherapy on tear drop poikilocytes and other peripheral blood findings in myelofibrosis. Pathology 1988; 20:7.</a></li><li><a class="nounderline abstract_t">Baker RI, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 1988; 40:267.</a></li><li><a class="nounderline abstract_t">Hasegawa DK, Bennett AJ, Coccia PF, et al. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 1980; 56:585.</a></li><li><a class="nounderline abstract_t">Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98:3249.</a></li><li><a class="nounderline abstract_t">Arora B, Sirhan S, Hoyer JD, et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005; 128:42.</a></li><li><a class="nounderline abstract_t">Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23:5688.</a></li><li><a class="nounderline abstract_t">Thiele J, Kvasnicka HM, Werden C, et al. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996; 22:303.</a></li><li><a class="nounderline abstract_t">Beer PA, Campbell PJ, Green AR. Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica 2010; 95:1960.</a></li><li><a class="nounderline abstract_t">Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90:1128.</a></li><li><a class="nounderline abstract_t">Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092.</a></li><li><a class="nounderline abstract_t">Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111:1862.</a></li><li><a class="nounderline abstract_t">Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997; 90:2127.</a></li><li><a class="nounderline abstract_t">Rozman C, Cervantes F, Rozman M, et al. Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis. Br J Haematol 1999; 104:574.</a></li><li><a class="nounderline abstract_t">Kaplan KR, Mitchell DG, Steiner RM, et al. Polycythemia vera and myelofibrosis: correlation of MR imaging, clinical, and laboratory findings. Radiology 1992; 183:329.</a></li><li class="breakAll">Landaw SA. Tissue imaging and cell survival studies for evaluating patients with hematologic disorders. In: Williams' Hematology, 5th ed, Beutler E, Lichtman MA, Coller B, et al. (Eds), McGraw-Hill, New York 1995. p.L12.</li><li><a class="nounderline abstract_t">Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379.</a></li><li><a class="nounderline abstract_t">Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369:2391.</a></li><li><a class="nounderline abstract_t">Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28:1472.</a></li><li><a class="nounderline abstract_t">Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123:3714.</a></li><li><a class="nounderline abstract_t">Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016; 127:325.</a></li><li><a class="nounderline abstract_t">Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895.</a></li><li><a class="nounderline abstract_t">Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012; 30:2981.</a></li><li><a class="nounderline abstract_t">Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105:973.</a></li><li><a class="nounderline abstract_t">Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991; 85:124.</a></li><li><a class="nounderline abstract_t">Ragni MV, Shreiner DP. Spontaneous "remission' of agnogenic myeloid metaplasia and termination in acute myeloid leukemia. Arch Intern Med 1981; 141:1481.</a></li><li><a class="nounderline abstract_t">Hernández JM, San Miguel JF, González M, et al. Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol 1992; 45:427.</a></li><li><a class="nounderline abstract_t">Passamonti F, Rumi E, Elena C, et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 2010; 150:719.</a></li><li><a class="nounderline abstract_t">Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; 112:2726.</a></li><li><a class="nounderline abstract_t">Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104:730.</a></li><li><a class="nounderline abstract_t">Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17:2954.</a></li><li><a class="nounderline abstract_t">Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112:231.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li class="breakAll">Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008. p.44.</li><li><a class="nounderline abstract_t">Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009; 6:627.</a></li><li><a class="nounderline abstract_t">Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood 2017; 129:3227.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">List AF, Kummet TD, Kerr DM. Acute myelofibrosis: response to recombinant human interferon alpha-2a. Leuk Res 1990; 14:321.</a></li><li><a class="nounderline abstract_t">Amberger DM, Saleem A, Kemp BL, Truong LD. Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature. Ann Clin Lab Sci 1990; 20:409.</a></li><li><a class="nounderline abstract_t">Dekmezian R, Kantarjian HM, Keating MJ, et al. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987; 59:1739.</a></li><li><a class="nounderline abstract_t">Singh M, Bofinger A, Taylor K, Ba Pe R. Myelodysplasia with myelofibrosis--a distinct subgroup within the myelodysplastic syndromes. Pathology 1994; 26:69.</a></li><li><a class="nounderline abstract_t">Vallespí T, Imbert M, Mecucci C, et al. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998; 83:258.</a></li><li><a class="nounderline abstract_t">Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS 1998; 106:495.</a></li><li><a class="nounderline abstract_t">Georgii A, Buhr T, Buesche G, et al. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996; 22 Suppl 1:15.</a></li><li><a class="nounderline abstract_t">Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117:5710.</a></li><li><a class="nounderline abstract_t">Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88:141.</a></li><li><a class="nounderline abstract_t">Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85:62.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179.</a></li><li><a class="nounderline abstract_t">Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012; 120:569.</a></li><li><a class="nounderline abstract_t">Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22:437.</a></li><li><a class="nounderline abstract_t">Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood 1994; 83:497.</a></li><li><a class="nounderline abstract_t">Stevenson JP, Schwarting R, Schuster SJ. Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis. Am J Hematol 1998; 59:79.</a></li><li><a class="nounderline abstract_t">Abildgaard N, Bendix-Hansen K, Kristensen JE, et al. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum. Br J Haematol 1997; 99:641.</a></li><li><a class="nounderline abstract_t">Schmidt U, Ruwe M, Leder LD. Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis. Nouv Rev Fr Hematol 1995; 37:159.</a></li><li><a class="nounderline abstract_t">Rashidi A, Roullet MR. Romiplostim-induced myelofibrosis. Blood 2013; 122:2001.</a></li><li><a class="nounderline abstract_t">Kiely JM, Silverstein MN. Metastatic carcinoma simulating agnogenic myeloid metaplasia and myelofibrosis. Cancer 1969; 24:1041.</a></li><li><a class="nounderline abstract_t">Yablonski-Peretz T, Sulkes A, Polliack A, et al. Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literature. Med Pediatr Oncol 1985; 13:92.</a></li><li><a class="nounderline abstract_t">O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.</a></li><li><a class="nounderline abstract_t">Pereira RM, Velloso ER, Menezes Y, et al. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol 1998; 17:219.</a></li><li><a class="nounderline abstract_t">Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore) 1994; 73:145.</a></li><li><a class="nounderline abstract_t">Bass RD, Pullarkat V, Feinstein DI, et al. Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature. Am J Clin Pathol 2001; 116:211.</a></li><li><a class="nounderline abstract_t">Rizzi R, Pastore D, Liso A, et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma 2004; 45:561.</a></li><li><a class="nounderline abstract_t">Popat U, Frost A, Liu E, et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 2006; 107:3486.</a></li><li><a class="nounderline abstract_t">Popat U, Frost A, Liu E, et al. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 2005; 143:466.</a></li><li><a class="nounderline abstract_t">Vergara-Lluri ME, Piatek CI, Pullarkat V, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol 2014; 45:2183.</a></li><li><a class="nounderline abstract_t">Pullarkat V, Bass RD, Gong JZ, et al. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol 2003; 72:8.</a></li><li><a class="nounderline abstract_t">Yetgin S, Ozsoylu S, Ruacan S, et al. Vitamin D-deficiency rickets and myelofibrosis. J Pediatr 1989; 114:213.</a></li><li><a class="nounderline abstract_t">Walka MM, Däumling S, Hadorn HB, et al. Vitamin D dependent rickets type II with myelofibrosis and immune dysfunction. Eur J Pediatr 1991; 150:665.</a></li><li><a class="nounderline abstract_t">Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328:171.</a></li><li><a class="nounderline abstract_t">Weinberg SG, Lubin A, Wiener SN, et al. Myelofibrosis and renal osteodystrophy. Am J Med 1977; 63:755.</a></li><li><a class="nounderline abstract_t">Nomura S, Ogawa Y, Osawa G, et al. Myelofibrosis secondary to renal osteodystrophy. Nephron 1996; 72:683.</a></li></ol></div><div id="topicVersionRevision">Topic 4529 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331505" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375922" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22389089" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1636666" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Agnogenic myeloid metaplasia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9766805" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Familial idiopathic myelofibrosis and multiple hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2278639" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myelofibrosis: a review of clinical and pathologic features and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207412" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207412" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6633248" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929105" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555513" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Unexplained pulmonary hypertension in chronic myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17851555" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22081434" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pruritus in primary myelofibrosis: clinical and laboratory correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21480207" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965680" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrombosis in primary myelofibrosis: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20884719" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735688" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Splenomegaly in 2,505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2,056 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704209" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227815" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3345875" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3345875" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12388506" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Typical and atypical presentations of extramedullary hemopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531481" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490917" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8503241" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1986577" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555137" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute respiratory failure due to extramedullary hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798379" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myelofibrosis, diffuse alveolar hemorrhage and radiation treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7071520" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intracranial myeloid metaplasia in myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192010" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intracranial extramedullary hematopoiesis: MR findings with pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141122" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Skin manifestation of agnogenic myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23877876" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cutaneous involvement by post-polycythemia vera myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406300" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cutaneous extramedullary hematopoiesis in myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2239880" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extramedullary hematopoiesis involving the esophagus in myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3357232" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Small intestinal myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1677228" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1754912" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Skeletal manifestations of granulocytic sarcoma (chloroma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408465" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/708641" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Erythrokinetic studies in myelofibrosis: their significance for prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843155" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of splenectomy on teardrop-shaped erythrocytes in agnogenic myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3374975" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of chemotherapy on tear drop poikilocytes and other peripheral blood findings in myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3356243" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6998521" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719361" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606548" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110028" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8819080" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534696" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079113" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : European consensus on grading bone marrow fibrosis and assessment of cellularity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488875" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029552" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310464" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Magnetic resonance imaging of the bone marrow in hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086797" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1561331" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Polycythemia vera and myelofibrosis: correlation of MR imaging, clinical, and laboratory findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1561331" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Polycythemia vera and myelofibrosis: correlation of MR imaging, clinical, and laboratory findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325356" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Somatic mutations of calreticulin in myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325359" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402162" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24786775" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423830" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988864" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826273" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Improving survival trends in primary myelofibrosis: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388582" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2042444" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6945070" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Spontaneous "remission' of agnogenic myeloid metaplasia and termination in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1597522" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Development of acute leukaemia after idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20560961" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404742" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk factors for leukemic transformation in patients with primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192432" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561375" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18401028" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19806146" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28351937" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2332985" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute myelofibrosis: response to recombinant human interferon alpha-2a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2073090" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2435399" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165032" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Myelodysplasia with myelofibrosis--a distinct subgroup within the myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573680" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637273" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951769" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21447832" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23349007" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19844986" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prodromal myeloproliferative neoplasms: the 2008 WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747083" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22700720" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728787" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8286747" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9723582" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9401078" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644355" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24175353" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Romiplostim-induced myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5353936" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Metastatic carcinoma simulating agnogenic myeloid metaplasia and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3982370" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924261" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9694056" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190037" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488067" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15160919" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autoimmune myelofibrosis: report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418333" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172450" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : New onset of myelofibrosis in association with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282037" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12508261" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536807" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Vitamin D-deficiency rickets and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1655462" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vitamin D dependent rickets type II with myelofibrosis and immune dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417383" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/930950" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Myelofibrosis and renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730443" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Myelofibrosis secondary to renal osteodystrophy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
